conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim may
price data jul
rate updat jul
currenc amount express
methodolog valu compani
senat financ committe chairman chuck grassley
democrat rank member ron wyden post
prescript drug price reduct act tuesday
although final bill need proceed
mark-up thursday get major vote full
committe could see chang proce
senat floor vote like mean bipartisan
agreement reach prior post share price
drug firm larg unmov news
think progress senat make less like
sever hh rule intern price benchmark
medicar part implement also mean
increasingli like legisl could hold price
increas extent make fair valu
estim chang news continu watch
updat senat follow thursday mark-up
hous like propos legisl
septemb caution possibl bipartisan
bill could pass senat fail hous
progress democrat will compromis
certain issu exampl medicar part direct
negoti includ pdpra regardless
expect overhang drug stock next sever
month drug price overhaul remain key topic
washington result continu see industri
under-valued despit strong product increasingli
overal propos pdpra similar
discuss recent analysi rebat rule dead
signific benefit pdpra compar
rebat rule cost congression budget offic
cbo estim rebat rule would result
billion extra feder spend year
assum current rebat withheld contrast
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit boost
gilead exposur cell therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
annual price increas top drug around
rebat rule dead suppli chain benefit drug firm
pressur estim drug firm exposur
anoth key part pdpra drug manufactur
perspect medicar part redesign could
implement would hit firm
expens drug hardest chang would cap out-
of-pocket cost previous patient paid drug cost
catastroph phase limit
patient enter catastroph coverag phase drug
firm would hook drug cost
elimin current coverag gap discount drug firm
pay cost coverag gap introduc
new respons higher spend level
discuss recent research see firm like gilead
hepat hiv treatment bristol/celgen cancer
therapi revlimid potenti expos peer
cbo estim pdpra would save taxpay
billion year billion save
medicaid mostli increas maximum rebat
billion save medicar within medicar
save larg split part redesign
billion inflation-reb polici billion
would forc drugmak pay addit rebat drug
medicar part part price increas
exceed inflat cpi-u roughli annual
addit two medicar polici would help
beneficiari lower pocket cost premium
total billion year cbo also assum
inflation-reb provis would reduc drug cost
patient privat insur part redesign
would substanti effect patient
think unclear impact pdpra could
patient cover privat insur drugmak could
continu rais price privat market simpli pay
addit rebat necessari medicar
among highest-profil provis pdpra
propos cap medicar part part price increas
inflationari level begin excess price
increas would need return medicar form
rebat part expect larg
impact even firm high exposur channel
biggest drug program take
larg price increas reimburs system alreadi
discourag instead reli high launch price
profit exampl among top drug medicar
part spend accord medicar drug
spend dashboard one saw averag annual price
increas
neulasta newer blockbust bristol opdivo
merck keytruda top annual price
increas part expect could
drug higher list price increas could
impact dashboard spend data indic averag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
